NEW YORK: Johnson & Johnson remains “very confident” in its coronavirus vaccine and hopes for a swift resolution from regulators over its profile, a senior executive said on Tuesday.

Johnson & Johnson Chief Financial Officer Joseph Wolk told CNBC “we remain very confident and very hopeful that the benefit-risk profile will play out.”

The comments came ahead of a decision expected later on Tuesday from Europe’s drug regulator on the safety of the single-shot vaccination.

United States pandemic advisor Anthony Fauci said the U.S is likely to announce its decision by Friday.

On April 14, U.S. health authorities advised a pause on the vaccine following 6 cases of critical blood clots out of almost 7 million American citizens who were inoculated.

Wolk said the company hopes “very shortly … perhaps as early as the end of this week, to have some resolution with how we are going to proceed.”

Asked if the U.S. decision to cut out the program inhibits public confidence in vaccines, Wolk said “I would hope that at the end of the week, the population in general will feel more confident in taking the vaccine.”

The comments came as J&J released first-quarter outcomes.

An earnings press release did not give further details on vaccine approval issues, but said the vaccine made $100 million in revenues in the U.S. during the period. J&J is selling the vaccine at cost.